Clinical Studies of Iron Chelators in Malaria

Acta Haematologica

Volumn 95, Issue 1, 1996, Pages 78-86

  Mabeza, George F ^a   Biemba, Godfrey ^b   Gordeuk, Victor R ^c  

^a UNIVERSITY OF THE WITWATERSRAND   (South Africa)

^b Macha Mission Hospital   (Zambia)

^c GEORGE WASHINGTON UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Cellular immunity; Cerebral malaria; Deferiprone; Desferrioxamine B; Iron chelation; Iron chelators; Lipid peroxidation; Malaria; Plasmodium falciparum; Plasmodium vivax

Indexed keywords

ANTIMALARIAL AGENT; CHELATING AGENT; CHLOROQUINE; DEFERIPRONE; DEFEROXAMINE; FANSIDAR; QUININE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIMALARIAL ACTIVITY; ARTICLE; BRAIN MALARIA; BRAIN TISSUE; CELLULAR IMMUNITY; CLINICAL TRIAL; COMA; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG MECHANISM; HELPER CELL; HUMAN; HYPOACUSIS; IMMUNE RESPONSE; INTRAVENOUS DRUG ADMINISTRATION; IRON CHELATION; LIPID PEROXIDATION; MAJOR CLINICAL STUDY; MALARIA; META ANALYSIS; NONHUMAN; PARASITOSIS; PLASMODIUM FALCIPARUM; PLASMODIUM VIVAX; PRIORITY JOURNAL; RAT; SUBCUTANEOUS DRUG ADMINISTRATION; T LYMPHOCYTE; THAILAND; TISSUE INJURY; VISUAL DISORDER; ZAMBIA;

ADULT; ANTIMALARIALS; CHILD; HUMANS; IRON CHELATING AGENTS; MALARIA; MALARIA, CEREBRAL; MALARIA, FALCIPARUM; MALARIA, VIVAX; RANDOMIZED CONTROLLED TRIALS; THAILAND; ZAMBIA;

EID: 0030043856     PISSN: 00015792     EISSN: 14219662     Source Type: Journal    
DOI: 10.1159/000203953     Document Type: Article

References (69)

1. Gilles HM: Management of Severe and Complicated Malaria: A Practical Handbook. Geneva, World Health Organization, 1991.
2. World Health Organization: Malaria Control in Countries Where Time-Limited Eradication Is Impracticable at Present. WHO Tech Report Ser 1974;537.
3. Greenberg AE, Lobcl HO: Mortality from Plasmodium falciparum in travellers from the United States, 1959 to 1987. Ann Intern Med 1990;113:326-327.
4. Clyde DF: Recent trends in the epidemiology and control of malaria. Epidemiol Rev 1987;9: 219-243.
5. Bezkorovainy A: Biochemistry of Nonheme Iron. New York, Plenum, 1980.
6. Scheibel LW, Sherman IW: Metabolism and organellar function during various stages of the life cycle: Proteins, lipids, nucleic acids and vitamins; in Wemsdorfer W, McGregor I (eds): Malaria: Principles and Practice of Malariolo-gy. New York. Churchill Livingstone, 1988. pp 219-252.
7. Wrigglesworth JM, Baum H: The biochemical features of iron; in Jacobs A, Worwood M (eds): Iron in Biochemistry and Medicine II: San Diego, Academic Press, 1980, pp 29-86.
8. Scheibel LW: Plasmodial parasite biology: Carbohydrate metabolism and related organellar function during various stages of the life cycle; in Wernsdorfer W, McGregor I (eds): Malaria: Principles and Practice of Malariology. New York, Churchill Livingstone, 1988, pp 171— 217.
9. 59Fe in Plasmodium falciparum in the presence of oxines. Prog Clin Biol Res 1989;313: 119-149.
10. Raventos-Suarez C, Pollack S, Nagel RL: Plasmodium falciparum. Inhibition of in vitro growth by deferoxamine. Am J Trop Med Hyg 1982;31:919-912.
11. Fritsch G, Sawatzki G, Treumer J, Jung A, Spria DT: Plasmodium falciparum: Inhibition in vitro with Iactoferrin, desferrithiocin, and desferricrocin. Exp Parasitol 1987;63:1-9.
12. Yinnon AM, Thcanacho EN, Grady RW, Spira DT, Hershko C: Antimalarial effect of HBED and other phenolic and catecholic iron chelators. Blood 1989;74:2166-2171.
13. Whitehead S, Peto TEA: Stage-depcdcnt effect of deferoxamine on growth of Plasmodium falciparum in vitro. Blood 1990;76:1250-1255.
14. Fritsch G, Treumer J, Spira DT, Jung A: Suppression of mouse infections with deferoxamine B. Exp Parasitol 1985;60:171-174.
15. Hershko C, Peto TEA: Deferoxamine inhibition of malaria is independent of host iron status. J Exp Med 1988;168:375-387.
16. Pollack S, Rossan RN, Davidson DE, Escaja-dillo A: Deferoxamine suppresses Plasmodium falciparum in Aotus monkeys. Proc Soc Exp Biol Med 1987;184:162-164.
17. Yang Y, Ranz A, Pan H, Zhang Z, Lin X, Meshnick SR: Daphnetin: A novel antimalarial agent with in vitro and in vivo acitvity. Am J Trop Med Hyg 1992;46:15.
18. Modell B, Berdoukas V: Desferrioxamine; in: The Clinical Approach to Thalassaemia. London, Grune &Stratton, 1984. pp 216-241.
19. Brittenham GM: Iron chelating agents; in: Current Therapy in Hematology Oncology 3. St. Louis, Mosby, 1987, pp 149-153.
20. uC-Desferrioxamine uptake into erythrocytes infected with Plasmodium falciparum. Z Parasitenkd 1986,72:106.
21. Hershko C, Wcatherall JD: Iron-chelating therapy. Crit Rev Clin Lab Sci 1988;26:303.
22. Gordeuk VR, Thuma PE, Brittenham GM, Zulu S, Simwanza P, M’hango A, Fleisch G, Parry D: Iron chelation with deferoxamine B in adults with asymptomatic Plasmodium falciparum parasitemia. Blood 1992;79:308-312.
23. Gordeuk VR, Thuma PE, Brittenham GM, Bicmba G, Zulu S, Simwanza G, Kalense P, M'hango A, Parry D, Poltera AA, Aikawa M: Iron chelation as a chemotherapeutic strategy for falciparum malaria. Am J Trop Med Hyg 1993;48:193-197.
24. Bunnag D, Poltera AA, Viravan C, Looareesu-wan S, Harinasuta KT, Schindlery C: Plasmod-icidal effect of desferrioxamine B in human vivax and falciparum malaria from Thailand. Acta Trop 1992;52:59-67.
25. Summers M, Jacobs A, Tudway D, Perera P, Ricketts C: Studies in desferrioxamine and fer-rioxamine in normal and iron-loaded subjects. Br J Haematol 1979;42:547-555.
26. Olivieri NF, Buncic JR, Chew E, Gallant T, Harrison RV, Keenan N, Logan W, Mitchell D, Ricci G. Skarf B, Taylor M, Freedman MH: Visual and auditory neurotoxicity in patients receiving subcutaneous deferoxamine infusions. N Engl J Med 1986;314:869-873.
27. Blake DR. Winyard P, Lunec J, Williams A, Good PA, Crewes SJ, Gutteridge JVC, Rowley D, Halliwell B, Cornish A, Hider RC: Cerebral and ocular toxicity induced by desferrioxamine. Q J Med 1985;56:345-355.
28. Poison RJ, Jawed A, Bomford A, Berry' H, Williams R: Treatment of rheumatoid arthritis with desferrioxamine: Relation between stores of iron before treatment and side effects. Br Med J 1985;291:448.
29. Porter JB, Huehns ER: The toxic effects of desferrioxamine. Ballieres Clin Haematol 1989;2: 459-474.
30. Balcerzak SP, Westerman MP, Heinle EW, Taylor FH: Measurement of iron stores using deferoxamine. Ann Intern Med 1968;68:518.
31. Harvey PWJ, Heywood PF, Galmc K, Zegans M, Habicht JP, Bradin B, Forsyth K, Alpers MP: The effect of iron chelation therapy on malarial infection in Papua Guinean school children is independent of host iron status. Am J Trop Med Hyg 1989;40:12-18.
32. Hcppner DG, Hallaway PE, Kontorghiorges GJ, Eaton JW: Antimalarial properties of orally active iron chelators. Blood 1988;72:358-361.
33. Olivieri N, Koren G, Herman C, Bentur Y, Chung D, Klein J, St Louis P, Freeman MH, McClelland RA, Templeton DM: Evaluation of the oral iron chelator l,2-dimethyl-3-hydroxy-pyricin-4-one (LI) in iron loaded patients: A randomised cross-over comparison with deferoxamine. Effect on iron balance and dose response studies. Lancet 1990;336:1275-1279.
34. Hershko C, Theanacho EN, Spira DT, Peter HH, Dobbin P, Hider RC: The effect of N-alkyl modification on the antimalarial activity of 3-hydroxypyridin-4-one oral iron chelators. Blood 1991;77:637-643.
35. Hershko C, Gordeuk VR, Thuma PE, Theanacho EN, Spira DT, Hider RC, Peto TEA, Brittenham GM: The antimalarial activity of iron chelators in animal models and humans with mild falciparum malaria. J Inorg Biochem 1992;47:267-277.
36. Olivieri NF. Koren G. Matsui D, Liu PP. Blcn-dis L, Cameron R, McClelland RA, Templeton DM: Reduction of tissue iron stores and normalization of serum ferritin during treatment with the oral iron chclator LI in thalassemia intermedia. Blood 1992;79:2741-2748.
37. Matsui D. Klein J, Herman C, Gruneau V, McClelland R, Chung D, St Louis P, Olivieri N, Koren G: Relationship between the pharmacokinetics and iron excretion pharmacodynamics of the new oral iron chelator 1,2-dimc-thyl-3-hydroxypyridin-4-one in patients with thalassaemia. Clin Pharmacol Ther 1991:50: 294-298.
38. Traorc O, Carnevale P, Kaptuc-Nochc L, M’Bede J, Desfontaine M, Elion J. Labie D. Negcl RL: Preliminary report on the use of desferrioxamine in the treatment of Plasmodium falciparum malaria. Am J Hematol 1991:37: 206-208.
39. Gordeuk VR. Thuma PE, Brittenham GM, McLaren CE. Parry D. Backcnstose A, Biemba G, Msiska R, Holmes L, McKinley E, Vargas L, Gilkeson R. Poltera AA: Effect of iron chelation therapy on recover from deep coma in children with cerebral malaria. N Engl J Med 1992;327:1473-1477.
40. Molyneux ME, Taylor TE, Wirima JJ, Borg-stein A: Clinical features and prognostic indicators in children w ith paediatric cerebral malaria: A study of 131 Malawian comatose children. Q J Med 1989:71:441 -459.
41. Phillips RE. Solomon T: Cerebral malaria in children. Lancet 1990;336:1355-1360.
42. Scott MD, Ranz A, Kuypers FA, Lubin BH, Meshnick SR: Parasite uptake of desferrioxamine: A prerequisite for antimalarial activity. BrJ Haematol 1990;75:598-602.
43. Loyevsky M. Lytton SD, Mester B, Libman J, Shanzer A, Cabantchik ZI: The antimalarial action of Dcsfcral involves a direct access route to erythrocytic (Plasmodium falciparum) parasites. J Clin Invest 1993;91:218-224.
44. Atkinson CT. Bayne MT, Gordeuk VR, Brittenham GM, Aikawa M: Stage-specific ultra-structural effects of desferrioxamine on Plasmodium falciparum in vitro. Am J Trop Med Hyg 199 i,45:593-601.
45. Reichard P. Ehrenberg A: Ribonuclcotide reductase - A radical enzyme. Science 1983;221: 514-519.
46. Cavanaugh PF, Porter CW, Tukalo D, Frankfurt DS. Pavelic ZP, Bergeron RJ: Characterization of L1210 cell growth inhibition by the bacterial iron chelators parabactin and compound II. Cancer Res 1985;45:4754-4759.
47. Bergeron RJ: Iron: A controlling nutrient in proliferative processes. Trends Biochem Sci 1986;11:133-136.
48. Mosmann TR, Coffman RL: TH1 and TH2 cells: Different patterns of lymphokine secretion lead to different functional properties. Annu Rev Immunol 1989;7:145-173.
49. Romagagni S: Induction of TH1 and TH2 responses: A key role for the ‘natural’ immune response? Immunol Today 1992;13:379-381.
50. Roitt IM, Brostoff J, Male DK: Immunology. St Louis, Mosby, 1993.
51. Weiss G, Fuchs D, Werner-Fclmayer G, Wächter H: Therapy of Plasmodium falciparum parasitemia with desferrioxamine. Blood 1992;80:843-844.
52. Mellouk S. Green SJ, Nacy CA, Hoffman SI: IFN-gamma inhibits development of Plasmodium berghei exoerythrocytic stages in hepato-cytes by and L-arginine pathway. J Immunol 1991:146:3971-3976.
53. Nussler A, Drapier JC, Renia L, Pied S, Milt-gen F, Gentilin M, Mazier D: /.-arginine dependent destruction of intrahepatic malaria parasites in response to tumor necrosis factor and/or interleukin 6 stimulation. Eur J Immunol 1991;21:227-230.
54. Weiss G, Fuchs D, Hausen A: Reibnegger G, Werner ER, Werner-Fclmayer G, Wächter H: Iron modulates intcrfcron-gamma effects in human myelomonocytic cell line THP-1. Exp Hematol 1992;20:605-610.
55. Weiss G, Werner-Fclmayer G. Werner ER, Grünewald K, Wächter H, Hentze MW: Iron regulates nitric oxide synthase activity by controlling nuclear transcription. J Exp Med 1994; 180:969-976.
56. Picot S, Petron F, Vuillez JP, Barbe G, Deloron P, Jacob MC. Chumpitazi B, Boudin C, Sheik-Zakkiudin I, Ambrosc-Thomas P: Neopterin levels in plasma during a longitudinal study in an area endemic for malaria. Clin Immunol Immunopathol 1993;67:273-276.
57. Fuchs D, Hausen A, Reibnegger G, Werner ER, Dietrich MP. Wächter H: Neopterin as a marker of activated cell-mediated immunity: Application on HIF infection. Immunol Today 1988;9:150-155.
58. MacPherson GG, Warrell MJ. Looareesuwan S, Warrell DA: Human cerebral malaria: A quantitative ultrastructural analysis of parasitised erythrocyte sequestration. Am J Pathol 1985;119:385-401.
59. Aikawa M: Human cerebral malaria. Am J TropMed Hyg 1988:39:3-10.
60. McCord JM: Oxygen-derived free radicals in postischemic tissue injury. N Engl J Med 1985; 312:159-163.
61. Henson PM. Johnson RB: Tissue injury in inflammation: Oxidants, proteinases, and cationic proteins. J Clin Invest 1987;79:669-674.
62. Sadrzadeh SMH, Graf E. Panter SS; Hallaway PE, Eaton JW: Hemoglobin: A biologic Fenton reagent. J Biol Chem 1984;259:14354-14356.
63. Sadrzadeh SM, Anderson DK, Panter SS, Hallaway PE, Eaton JW: Hemoglobin potentiates central nervous system damage. J Clin Invest 1987;79:662-664
64. Alvarez-Hernandez X, Liceaga J, McKay IC, Brock JH: Induction of hypoferrcmia and modulation of macrophage iron metabolism by tumor necrosis factor. Lab Invest 1989:61:319— 322.
65. Dinarello CA, Cannon JG, Mier JW. Bernheim HA, Lo Preste G, Lynn DL, Love RN, Webb AC, Auron PE, Reuben RC, Rich A, Wolff SM, Putney SD: Multiple biological activities of human recombinant interleukin-1. J Clin Invest 1986;77:1734-1739.
66. Pootrakul P, Kitcharoen K, Yansukon P, Wasi P. Fucharoen S, Charoenlarp P. Brittenham G, Pippard MJ, Finch CA: The effect of erythroid hyperplasia on iron balance. Blood 1988:71: 1124-1129.
67. Ward PA, Till GO, Kunkel R, Beauchamp C: Evidence for role of hydroxyl radical in complement and neutrophil-dependent injur. J Clin Invest 1983;72:369-371.
68. Gordeuk VR, Thuma PE, McLaren CE, Biemba G. Zulu S, Poltera AA, Askin JE, Brittenham GM: Transferrin saturation and recovery from coma in cerebral malaria. Blood, 1995;85: 3297-3301.
69. Ambrosio G, Zweier JL, Jacobus WE, Weis-feldt ML, Flaherty JT: Improvement of postischemic myocardial function and metabolism induced by administration of deferoxamine at the time of reflow: The role of iron in the pathogenesis of reperfusion injur. Circulation 1987; 76:906-915.